Product Data Sheet

TLR4-IN-C34

Cat. No.: HY-107575

CAS No.: 40592-88-9Molecular Formula: $C_{17}H_{27}NO_{9}$ Molecular Weight: 389.4

Target: Toll-like Receptor (TLR)

Pathway: Immunology/Inflammation

Storage: Powder -20°C 3 years

4°C 2 years
In solvent -80°C 2 years

-20°C 1 year

SOLVENT & SOLUBILITY

In Vitro

DMSO: 250 mg/mL (642.01 mM; Need ultrasonic) H₂O: 33.33 mg/mL (85.59 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.5681 mL	12.8403 mL	25.6805 mL
	5 mM	0.5136 mL	2.5681 mL	5.1361 mL
	10 mM	0.2568 mL	1.2840 mL	2.5681 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: PBS Solubility: 7.69 mg/mL (19.75 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
- 2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 6.25 mg/mL (16.05 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- β -CD in saline) Solubility: \geq 6.25 mg/mL (16.05 mM); Clear solution
- 4. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 6.25 mg/mL (16.05 mM); Clear solution

BIOLOGICAL ACTIVITY

DescriptionTLR4-IN-C34 is an orally active TLR4 inhibitor and reduces systemic inflammation in models of endotoxemia and necrotizing enterocolitis^{[1][2]}.

IC₅₀ & Target TLR4

In Vivo

TLR4-IN-C34 (C34, 1 mg/kg, orally daily) could attenuate NEC severity and demonstrates a marked preservation of the intestinal mucosa^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Experimental NEC induced in 7-8 day old mice ^[1] .	
Dosage:	1 mg/kg.	
Administration:	Orally every morning.	
Result:	Attenuated intestinal inflammation.	

CUSTOMER VALIDATION

- EMBO J. 2021 Apr 21;e106188.
- Cell Commun Signal. 2023 May 1;21(1):86.
- Front Pharmacol. 2022 Jul 22;13:920928.
- Eur J Pharmacol. 2022 Sep 21;175294.
- Sci Rep. 2023 Nov 9;13(1):19440.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Neal MD, et al. Discovery and validation of a new class of small molecule Toll-like receptor 4 (TLR4) inhibitors. PLoS One. 2013 Jun 12;8(6):e65779.

[2]. Wipf P, et al. Synthesis of anti-inflammatory α -and β -linked acetamidopyranosides as inhibitors of toll-like receptor 4 (TLR4). Tetrahedron Lett. 2015 Jun 3;56(23):3097-3100.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA